PLYMOUTH, Mich. and ROLLE, Switzerland, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Garrett Motion Inc. (Nasdaq: GTX), a leading differentiated automotive technology provider, today announced that it will publish its fourth‑quarter financial results on Thursday, February 19, 2026, prior to the opening of the market trading in the United States. Garrett will host a conference call that same day at 8:30 am EST / 2:30 pm CET. To participate in the conference call, please dial +1-877-883-0383 (U.S.) or +1-412-902-6506 (i ...

Core Viewpoint - Arch Biopartners Inc. has appointed Dr. Patrick Vink as the new Chairman of the Board of Directors, effective January 15, 2026, following the retirement of Claude Allary [1][5]. Company Leadership - Dr. Patrick Vink has extensive experience in the pharmaceutical industry, having served as an advisor since 2015 and held various board positions in public and private companies across North America and Europe [2]. - His previous roles include Executive Vice President and Chief Operating Officer of Cubist Pharmaceuticals, where he oversaw operations until its $9.5 billion acquisition by Merck in 2015 [3]. - Dr. Vink has a history with Arch Biopartners, having served as a director from December 2016 to December 2019 and as a Strategic Advisor thereafter [3]. Company Development - The appointment of Dr. Vink is seen as beneficial for Arch Biopartners as the company advances its acute kidney injury Phase II trials and chronic kidney disease program [4]. - The company is focused on developing novel drugs for acute kidney injury (AKI) and chronic kidney disease (CKD), targeting serious unmet needs affecting over 800 million people globally [7]. Board Changes - Claude Allary, who has been a director since 2014, has retired, contributing significantly to Arch's evolution into a leading kidney therapeutics company [5][6].

Core Insights - MAX Power Mining Corp. has confirmed Canada's first subsurface Natural Hydrogen system with the successful drilling of the Lawson well in Saskatchewan, marking a significant milestone in the clean energy sector [1][20][33] Group 1: Discovery and Geological Insights - The Lawson well achieved hydrogen concentrations of up to 286,000 ppm (28.6% H₂), indicating a viable Natural Hydrogen system [7][8] - The geological model for Natural Hydrogen accumulations has been validated, suggesting potential for scalability across the 475-km-long Genesis Trend and MAX Power's 1.3-million acre land package [3][14] - The Genesis Trend is strategically located near the Regina–Moose Jaw Industrial Corridor, which has strong hydrogen demand, and is adjacent to the Prairie Evaporite, known for its potash reserves [4][20] Group 2: Next Steps and Development Plans - MAX Power plans to advance the Lawson discovery towards commercial evaluation, including a confirmatory well and a 3D seismic survey to define reservoir geometry [11][13] - The company will integrate data from Lawson into its AI-assisted Large Earth Model for Natural Hydrogen exploration (MAXX LEMI), aimed at optimizing targeting and accelerating discovery [11][21] - Stakeholder engagement with local industrial and energy users, as well as national and global companies, is part of the strategy to develop the Natural Hydrogen sector [13][21] Group 3: Market Position and Future Outlook - The Lawson discovery positions MAX Power as a leader in the emerging Natural Hydrogen industry, transitioning from theoretical exploration to verified subsurface reality [20][21] - The company has identified multiple de-risked follow-up targets along the Genesis Trend, enhancing its potential for repeatable and scalable Natural Hydrogen exploration [14][21] - With strong financial backing and strategic partnerships, MAX Power is well-positioned for long-term shareholder value creation in the clean energy market [21]

Core Viewpoint - Vivos Therapeutics, Inc. has entered into a definitive agreement for the immediate exercise of outstanding warrants, which will generate approximately $4.64 million in gross proceeds for the company [1][4]. Group 1: Financial Details - The company will exercise warrants to purchase up to 1,982,356 shares at a reduced exercise price of $2.34 per share, down from original prices ranging from $3.83 to $5.05 [1]. - In exchange for the cash exercise of existing warrants, Vivos will issue new unregistered warrants to purchase up to 3,964,712 shares at an exercise price of $2.09 per share [3]. - The offering is expected to close on or about January 20, 2026, subject to customary closing conditions [4]. Group 2: Company Overview - Vivos Therapeutics focuses on developing and commercializing innovative diagnostic and treatment methods for sleep-related breathing disorders, particularly obstructive sleep apnea (OSA) [7]. - The company’s devices are FDA-cleared for treating OSA in both adults and children, with its Complete Airway Repositioning and Expansion (CARE) devices being the only FDA 510(k) cleared technology for severe OSA in adults [7]. - OSA affects over 1 billion people globally, with 90% undiagnosed, highlighting a significant market opportunity for Vivos [8]. Group 3: Strategic Intent - Vivos aims to empower healthcare providers to address the complex needs of OSA patients through innovative technology, education, and collaborations with sleep healthcare providers [9]. - The company promotes its treatment approach, known as The Vivos Method, which is a nonsurgical, noninvasive, and nonpharmaceutical solution for OSA [10].

PERTH, Australia, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Locafy Limited (Nasdaq: LCFY, LCFYW) (“Locafy” or the “Company”), a global software-as-a-service technology company specializing in location-based digital marketing solutions, today announced the formal expansion of its partnership with Experience.com, under which Experience will sell Locafy’s Localizer product across the United States. Under the expanded agreement, Experience will offer Locafy’s Localizer solution alongside its core reviews and reputation ...

In 2025, Forever Network delivered more than 20 billion impressions across its platforms to 450 million people Recently announced collaboration with Crypto.com sets the stage for High Roller’s entry into the regulated U.S. prediction markets Las Vegas, Nevada, Jan. 16, 2026 (GLOBE NEWSWIRE) -- High Roller Technologies, Inc. (“High Roller”) (NYSE: ROLR), operator of the award-winning, premium online casino brands High Roller and Fruta, today announced it has signed a non-binding Letter of Intent (“LOI”) with ...

Achieving Transformative Impact on the Workforce by Implementing AI Recruitment, Smart Scheduling, and Digital Agent AUO Suzhou Fab AUO Suzhou Fab has been recognized by the World Economic Forum (WEF)’s Global Lighthouse Network (GLN) in the Talent category, becoming the first in the global display industry to receive this honor. HSINCHU, Taiwan, Jan. 16, 2026 (GLOBE NEWSWIRE) -- AUO announced today (16th) that its Suzhou Fab has been recognized by the World Economic Forum (WEF)’s Global Lighthouse Netwo ...

Governance evolution follows elimination of major convertible debt, recent funding, and improved capital structure Company advances governance framework aligned with shareholder interests and future listing requirements West Palm Beach, FL, Jan. 16, 2026 (GLOBE NEWSWIRE) -- QHSLab Inc. (the “Company”) (OTCQB: USAQ), a digital health infrastructure company supporting primary care practices, today announced that it has initiated a formal process to expand its board of directors by adding independent members. ...

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES GRAND JUNCTION, Colo., Jan. 16, 2026 (GLOBE NEWSWIRE) -- ProStar Holdings Inc. (“ProStar®” or the “Company”) (TSXV: MAPS) (OTCQX: MAPPF) (FSE: 5D00), developer of PointMan® Precision Mapping Solutions® and the LinQD™ enterprise integration platform, is pleased to announce that the Company intends to complete a non-brokered private placement with a director of the Company of secured convertible debentures of t ...

Helsinki, 16 January 2026 – Multitude Capital Oyj (the “Company”), a wholly-owned subsidiary of Multitude AG, announces that the issued senior unsecured notes have been affirmed at 'B+' with a Recovery Rating of 'RR4' by Fitch Ratings. For further information, please contact: Adam Hansson Tönning Head of IR and Treasury Phone: +46733583171 E-mail: adam.tonning@multitude.com About Multitude Capital Oyj: Multitude Capital Oyj acts as Multitude Group’s funding vehicle, issuing bonds to support liquidity for ...